ANNX saw its Momentum Indicator move below the 0 level on October 12, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned negative. In 72 of the 80 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANNX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for ANNX entered a downward trend on October 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ANNX's RSI Oscillator exited the oversold zone, 27 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 57 of 64 cases where ANNX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Moving Average Convergence Divergence (MACD) for ANNX just turned positive on October 19, 2026. Looking at past instances where ANNX's MACD turned positive, the stock continued to rise in 38 of 45 cases over the following month. The odds of a continued upward trend are 84%.
Following a +1.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANNX advanced for three days, in 224 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
ANNX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Seasonality Score of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 59 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.902) is normal, around the industry mean (3.009). P/E Ratio (-3.389) is within average values for comparable stocks, (-1.027). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.622) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. ANNX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANNX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The 10-day moving average for DMAC crossed bullishly above the 50-day moving average on September 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 18 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 62 cases where DMAC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on DMAC as a result. In 77 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
DMAC moved above its 50-day moving average on September 17, 2026 date and that indicates a change from a downward trend to an upward trend.
The 50-day moving average for DMAC moved above the 200-day moving average on October 13, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +14.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where DMAC advanced for three days, in 216 of 256 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
DMAC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 123 of 157 cases where DMAC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
The 10-day RSI Indicator for DMAC moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 26 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 87%.
The Moving Average Convergence Divergence Histogram (MACD) for DMAC turned negative on October 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 39 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DMAC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. DMAC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 40 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 68 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.195) is normal, around the industry mean (3.009). P/E Ratio (-12.042) is within average values for comparable stocks, (-1.027). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.622) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
ANNX | DMAC | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 62 | 87 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 59 Fair valued | 70 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 40 | |
SMR RATING 1..100 | 99 | 99 | |
PRICE GROWTH RATING 1..100 | 63 | 39 | |
P/E GROWTH RATING 1..100 | 16 | 68 | |
SEASONALITY SCORE 1..100 | 12 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ANNX's Valuation (59) in the null industry is in the same range as DMAC (70) in the Biotechnology industry. This means that ANNX’s stock grew similarly to DMAC’s over the last 12 months.
DMAC's Profit vs Risk Rating (40) in the Biotechnology industry is somewhat better than the same rating for ANNX (100) in the null industry. This means that DMAC’s stock grew somewhat faster than ANNX’s over the last 12 months.
DMAC's SMR Rating (99) in the Biotechnology industry is in the same range as ANNX (99) in the null industry. This means that DMAC’s stock grew similarly to ANNX’s over the last 12 months.
DMAC's Price Growth Rating (39) in the Biotechnology industry is in the same range as ANNX (63) in the null industry. This means that DMAC’s stock grew similarly to ANNX’s over the last 12 months.
ANNX's P/E Growth Rating (16) in the null industry is somewhat better than the same rating for DMAC (68) in the Biotechnology industry. This means that ANNX’s stock grew somewhat faster than DMAC’s over the last 12 months.
| ANNX | DMAC | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 69% | 1 day ago 87% |
| Stochastic ODDS (%) | 1 day ago 89% | 1 day ago 87% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 82% |
| MACD ODDS (%) | 1 day ago 84% | 1 day ago 80% |
| TrendWeek ODDS (%) | 1 day ago 87% | 1 day ago 82% |
| TrendMonth ODDS (%) | 1 day ago 87% | 1 day ago 81% |
| Advances ODDS (%) | 16 days ago 85% | 1 day ago 84% |
| Declines ODDS (%) | 5 days ago 89% | 7 days ago 81% |
| BollingerBands ODDS (%) | 1 day ago 70% | 1 day ago 89% |
| Aroon ODDS (%) | 1 day ago 87% | 1 day ago 78% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ANNX’s FA Score shows that 1 FA rating(s) are green while DMAC’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ANNX’s TA Score shows that 5 TA indicator(s) are bullish while DMAC’s TA Score has 8 bullish TA indicator(s).
ANNX (@Biotechnology) experienced а 0.00% price change this week, while DMAC (@Biotechnology) price change was +10.87% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.45%. For the same industry, the average monthly price growth was -16.03%, and the average quarterly price growth was -14.84%.
ANNX is expected to report earnings on Nov 09, 2026.
DMAC is expected to report earnings on Nov 11, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, ANNX has been loosely correlated with DYN. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ANNX jumps, then DYN could also see price increases.
| Ticker / NAME | Correlation To ANNX | 1D Price Change % | ||
|---|---|---|---|---|
| ANNX | 100% | -4.49% | ||
| DYN - ANNX | 44% Loosely correlated | +6.83% | ||
| DMAC - ANNX | 44% Loosely correlated | +10.17% | ||
| SVRA - ANNX | 43% Loosely correlated | +2.81% | ||
| RCKT - ANNX | 42% Loosely correlated | +4.46% | ||
| SLDB - ANNX | 41% Loosely correlated | +8.11% | ||
More | ||||
A.I.dvisor indicates that over the last year, DMAC has been loosely correlated with VIR. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if DMAC jumps, then VIR could also see price increases.
| Ticker / NAME | Correlation To DMAC | 1D Price Change % | ||
|---|---|---|---|---|
| DMAC | 100% | +10.17% | ||
| VIR - DMAC | 45% Loosely correlated | +5.19% | ||
| EDIT - DMAC | 45% Loosely correlated | +6.61% | ||
| TSHA - DMAC | 44% Loosely correlated | +4.31% | ||
| ANNX - DMAC | 42% Loosely correlated | -4.49% | ||
| SLDB - DMAC | 41% Loosely correlated | +8.11% | ||
More | ||||